4.7 Article

Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 313, 期 10, 页码 1029-1036

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2015.1206

关键词

-

资金

  1. Netherlands Organisation for Scientific Research (NWO) [91612122]
  2. CardioVascular Research Initiative [CVON2011-19]
  3. European Union (TransCard) [FP7-603091-2]
  4. Amgen
  5. Pfizer
  6. Roche
  7. Sanofi
  8. AstraZeneca
  9. Netherland Heart Foundation (NHS) [2010T082]
  10. Aegerion
  11. Boehringer Ingelheim
  12. Cerenis
  13. Eli Lilly
  14. Genzyme
  15. JSiS
  16. MSD
  17. Novartis
  18. Regeneron

向作者/读者索取更多资源

IMPORTANCE Familial hypercholesterolemia is characterized by impaired uptake of cholesterol in peripheral tissues, including the liver and the pancreas. In contrast, statins increase the cellular cholesterol uptake and are associated with increased risk for type 2 diabetes mellitus. We hypothesize that transmembrane cholesterol transport is linked to the development of type 2 diabetes. OBJECTIVE To assess the association between type 2 diabetes prevalence and familial hypercholesterolemia. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study in all individuals (n = 63 320) who underwent DNA testing for familial hypercholesterolemia in the national Dutch screening program between 1994 and 2014. EXPOSURES Deleteriousness and nondeleteriousness of familial hypercholesterolemia mutations were based on literature or laboratory function testing. Low-density lipoprotein (LDL) receptor mutations were considered more severe than apolipoprotein B gene (APOB) mutations, and receptor-negative LDL receptor mutations were considered more severe than receptor-deficient mutations. MAIN OUTCOMES AND MEASURES Prevalence of type 2 diabetes. RESULTS The prevalence of type 2 diabetes was 1.75% in familial hypercholesterolemia patients (n = 440/25 137) vs 2.93% in unaffected relatives (n = 1119/38 183) (P <.001; odds ratio [OR], 0.62 [95% CI, 0.55-0.69]). The adjusted prevalence of type 2 diabetes in familial hypercholesterolemia, determined using multivariable regression models, was 1.44% (difference, 1.49% [95% CI, 1.24%-1.71%]) (OR, 0.49 [95% CI, 0.41-0.58]; P <.001). The adjusted prevalence of type 2 diabetes by APOB vs LDL receptor gene was 1.91% vs 1.33% (OR, 0.65 [95% CI, 0.48-0.87] vs OR, 0.45 [95% CI, 0.38-0.54]), and the prevalence for receptor-deficient vs receptor-negative mutation carriers was 1.44% vs 1.12%(OR, 0.49 [95% CI, 0.40-0.60] vs OR, 0.38 [95% CI, 0.29-0.49]), respectively (P for trend <. 001 in both comparisons). CONCLUSIONS AND RELEVANCE In a cross-sectional analysis in the Netherlands, the prevalence of type 2 diabetes among patients with familial hypercholesterolemia was significantly lower than among unaffected relatives, with variability by mutation type. If this finding is confirmed in longitudinal analysis, it would raise the possibility of a causal relationship between LDL receptor-mediated transmembrane cholesterol transport and type 2 diabetes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据